RET (E762Q)

RET · Variant type: point · HGVS: p.E762Q

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Selpercatinib	99.4%	0.6%	96.72
2	Tenalisib	99.0%	1.0%	97.98
3	Tivozanib	98.7%	1.3%	92.42
4	Pralsetinib	98.1%	1.9%	93.43
5	Gilteritinib	96.7%	3.3%	88.97
6	Erdafitinib	96.7%	3.3%	95.71
7	Fedratinib	96.7%	3.3%	96.21
8	Alpelisib	96.6%	3.4%	97.22
9	Entrectinib	95.9%	4.1%	93.69
10	Quizartinib	95.2%	4.8%	99.50
11	Sunitinib	94.1%	5.9%	91.73
12	Sorafenib	93.8%	6.2%	96.72
13	Repotrectinib	92.3%	7.7%	84.21
14	Vandetanib	92.1%	7.9%	95.74
15	Nintedanib	91.7%	8.3%	90.23
16	Brigatinib	91.7%	8.3%	82.96
17	Ripretinib	91.6%	8.4%	92.95
18	Ponatinib	91.2%	8.8%	78.23
19	Alectinib	90.6%	9.4%	95.49
20	Regorafenib	89.8%	10.2%	95.99
21	Lenvatinib	89.8%	10.2%	97.74
22	Apatinib	89.7%	10.3%	97.73
23	Cabozantinib	89.4%	10.6%	92.73
24	Futibatinib	86.1%	13.9%	98.48
25	Avapritinib	75.1%	24.9%	97.73

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Selpercatinib	99.4%	100.0%	-0.6%
Tenalisib	99.0%	98.5%	+0.5%
Tivozanib	98.7%	99.7%	-1.0%
Pralsetinib	98.1%	100.0%	-1.9%
Gilteritinib	96.7%	100.0%	-3.3%
Erdafitinib	96.7%	94.7%	+2.1%
Fedratinib	96.7%	99.9%	-3.1%
Alpelisib	96.6%	99.6%	-3.0%
Entrectinib	95.9%	99.6%	-3.7%
Quizartinib	95.2%	—	—
Sunitinib	94.1%	97.2%	-3.1%
Sorafenib	93.8%	94.0%	-0.2%
Repotrectinib	92.3%	—	—
Vandetanib	92.1%	98.6%	-6.5%
Nintedanib	91.7%	100.0%	-8.3%
Brigatinib	91.7%	94.9%	-3.2%
Ripretinib	91.6%	—	—
Ponatinib	91.2%	100.0%	-8.8%
Alectinib	90.6%	97.8%	-7.2%
Regorafenib	89.8%	98.7%	-8.9%
Lenvatinib	89.8%	98.8%	-9.1%
Apatinib	89.7%	—	—
Cabozantinib	89.4%	97.5%	-8.1%
Futibatinib	86.1%	97.7%	-11.6%
Avapritinib	75.1%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.2ms